Eve Therese Rodler

Title(s)Associate Adjunct Professor, Hematology and Oncology
SchoolSchool of Medicine
AddressCancer Ctr So, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2023 02; 24(2):162-174. Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN. PMID: 36623515; PMCID: PMC9924094.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    2. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163. Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. PMID: 36215947; PMCID: PMC10204709.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    3. Reply to T. Shimoi et al and Y. Shimanuki et al. J Clin Oncol. 2021 11 01; 39(31):3522-3524. Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. PMID: 34554848; PMCID: PMC8547907.
      View in: PubMed   Mentions: 2     Fields:    
    4. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021 08 10; 39(23):2539-2551. Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. PMID: 34092112; PMCID: PMC8577688.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    5. A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. Clin Breast Cancer. 2022 01; 22(1):32-42. Symonds L, Jenkins I, Linden HM, Kurland B, Gralow JR, Gadi VVK, Ellis GK, Wu Q, Rodler E, Chalasani P, Chai X, Riedel J, Stopeck A, Brown-Glaberman U, Specht JM. PMID: 34158245; PMCID: PMC8611115.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    6. Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. Sarcoma. 2020; 2020:7935475. Baird K, Glod J, Steinberg SM, Reinke D, Pressey JG, Mascarenhas L, Federman N, Marina N, Chawla S, Lagmay JP, Goldberg J, Milhem M, Loeb DM, Butrynski JE, Turpin B, Staddon A, Spunt SL, Jones RL, Rodler ET, Schuetze SM, Okuno SH, Helman L. PMID: 32398945; PMCID: PMC7211262.
      View in: PubMed   Mentions: 11  
    7. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. Clin Breast Cancer. 2019 04; 19(2):e283-e296. Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C, Seattle Cancer Care Alliance Network Investigators, Specht J. PMID: 30737173; PMCID: PMC6440867.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    8. Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. Med Oncol. 2017 Aug 29; 34(10):167. Jones RL, Katz D, Loggers ET, Davidson D, Rodler ET, Pollack SM. PMID: 28852958; PMCID: PMC5574947.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    9. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res. 2016 06 15; 22(12):2855-64. Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM. PMID: 26801247; PMCID: PMC4911292.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCellsCTClinical Trials
    10. Treatment of chest wall sarcomas: a single-institution experience over 20 years. Am J Clin Oncol. 2015 Feb; 38(1):80-6. Burt A, Berriochoa J, Korpak A, Rodler E, Jones RL, Weisstein J, Patel S. PMID: 23563212.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    11. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. Otolaryngol Head Neck Surg. 2014 Dec; 151(6):976-83. Chang AE, Chai X, Pollack SM, Loggers E, Rodler E, Dillon J, Parvathaneni U, Moe KS, Futran N, Jones RL. PMID: 25257906.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    12. A contemporary large single-institution evaluation of resected retroperitoneal sarcoma. Ann Surg Oncol. 2014 Jul; 21(7):2150-8. Bremjit PJ, Jones RL, Chai X, Kane G, Rodler ET, Loggers ET, Pollack SM, Pillarisetty VG, Mann GN. PMID: 24615180.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    13. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013 Dec 15; 19(24):6902-11. Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY, Vetto JT, Pommier RF, Mansoor A, Beckett BR, Tudorica A, Mori M, Holtorf ML, Afzal A, Woodward WJ, Rodler ET, Jones RL, Huang W, Ryan CW. PMID: 24132922; PMCID: PMC3869565.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    14. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013 Jun; 30(2):501. Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL. PMID: 23456619.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    15. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb; 13(2):211-23. Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. PMID: 23406562.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    16. Perioperative management of hemostasis. . 2013 Jan 1; 223-233. Dutia DM, Rodler RE, Wun WT. .
      View in: Publisher Site   Mentions:
    17. Systemic therapy in primary angiosarcoma of the spleen. Rare Tumors. 2012 Oct 10; 4(4):e55. Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL. PMID: 23372919; PMCID: PMC3557569.
      View in: PubMed   Mentions: 13  
    18. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res. 2012 Jun 25; 2(1):34. Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM. PMID: 22731662; PMCID: PMC3444390.
      View in: PubMed   Mentions: 18  
    19. NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012; 7(2):e32165. Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. PMID: 22384167; PMCID: PMC3288075.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    20. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012 Sep 15; 118(18):4564-70. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. PMID: 22359263; PMCID: PMC3361576.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    21. (18)F-FDG PET in sarcoma treatment response imaging. Am J Nucl Med Mol Imaging. 2011; 1(1):47-53. Eary JF, Hawkins DS, Rodler ET, Conrad EU. PMID: 23133794; PMCID: PMC3477719.
      View in: PubMed   Mentions: 28  
    22. Immune-based therapies for sarcoma. Sarcoma. 2011; 2011:438940. Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL. PMID: 21331153; PMCID: PMC3034923.
      View in: PubMed   Mentions: 21  
    23. NCCN Clinical Practice Guidelines Cancer-related fatigue. J Natl Compr Canc Netw. 2010 Aug; 8(8):904-31. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. PMID: 20870636.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    24. Current treatment options in triple negative breast cancer. Breast Dis. 2010; 32(1-2):99-122. Rodler E, Korde L, Gralow J. PMID: 21778572.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    25. Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature. Am J Hematol. 2004 Apr; 75(4):231-8. Rodler E, Welborn J, Hatcher S, Unger K, Larkin E, Gumerlock PH, Wun T, Richman C. PMID: 15054816.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    With one click, see people who:

    Mentor

    Offer Student Projects

    Run Clinical Trials

    See more options in the Advanced Search tab

    Eve's Networks
    Concepts (143)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (6)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-2-gbbe5f151 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California